Valuation Neuland Laboratories Limited

Stocks

Market Closed - Bombay S.E. 10:02:26 30/10/2026 GMT			5-day change	1st Jan Change
19,701.10 ^INR	+2.21%		+4.09%	+29.70%

09-15	Neuland Laboratories Limited Accelerates Peptide Manufacturing Expansion with Operational Module and Additional Capacity Expansion Underway	CI
09-08	Indian shares on track for muted open as oil climbs on rising Mideast risks	RE

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	13,171	23,087	80,588	154,946	154,121	252,763	-	-
Change	-	75.28%	249.07%	92.27%	-0.53%	64%	-	-
Enterprise Value (EV) ¹	13,171	23,087	80,374	153,929	153,584	255,452	254,341	251,085
Change	-	75.28%	248.14%	91.52%	-0.22%	66.33%	-0.44%	-1.28%
P/E	20.6x	14.1x	26.9x	-	42.3x	52.9x	40.5x	29.8x
PBR	1.58x	-	6.32x	10.2x	8.27x	11x	8.76x	7x
PEG	-	0x	0.3x	-	-	1.7x	1.3x	0.8x
Capitalization / Revenue	1.38x	1.94x	5.17x	10.5x	7.62x	10.5x	8.7x	7.27x
EV / Revenue	1.38x	1.94x	5.16x	10.4x	7.59x	10.6x	8.75x	7.22x
EV / EBITDA	9.24x	8.49x	17.4x	47.6x	26.7x	35.3x	27.3x	20.8x
EV / EBIT	14.1x	-	19.9x	59.7x	31.8x	41.2x	30.7x	23.7x
EV / FCF	-35.3x	13.5x	68.4x	139x	-304x	57.2x	62.9x	41.8x
FCF Yield	-2.83%	7.41%	1.46%	0.72%	-0.33%	1.75%	1.59%	2.39%
Dividend per Share ²	-	10	14	12	34	22.69	30.13	57.02
Rate of return	-	0.56%	0.22%	0.1%	0.28%	0.12%	0.15%	0.29%
EPS ²	49.74	127.4	233.9	-	283.7	372.7	486.5	661.4
Distribution rate	-	7.85%	5.99%	-	12%	6.09%	6.19%	8.62%
Net sales ¹	9,511	11,912	15,586	14,768	20,230	24,177	29,057	34,789
EBITDA ¹	1,426	2,718	4,626	3,233	5,745	7,227	9,330	12,070
EBIT ¹	935.8	-	4,029	2,577	4,828	6,207	8,281	10,592
Net income ¹	638.2	1,635	3,001	2,601	3,640	4,798	6,265	8,532
Net Debt ¹	-	-	-214.1	-1,017	-536.9	2,690	1,578	-1,678
Reference price ²	1,026.60	1,799.45	6,281.30	12,076.95	12,012.65	19,701.10	19,701.10	19,701.10
Nbr of stocks (in thousands)	12,830	12,830	12,830	12,830	12,830	12,830	-	-
Announcement Date	10/05/22	11/05/23	10/05/24	15/05/25	12/05/26	-	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
NEULAND LABORATORIES LIMITED	51.72x	10.34x	34.59x	0.12%	2.6B
ELI LILLY AND COMPANY	40.35x	13.85x	30.26x	0.5%	1,224B
JOHNSON & JOHNSON	40.28x	6.76x	19.02x	1.94%	662B
ABBVIE INC.	38.08x	8.51x	17.61x	2.36%	514B
ROCHE HOLDING AG	21.65x	5.25x	13.07x	2.49%	388B
MERCK & CO., INC.	106.67x	5.95x	25.48x	2.33%	361B
NOVARTIS AG	22.86x	5.89x	14.22x	2.75%	302B
ASTRAZENECA PLC	22.82x	4.6x	13.15x	1.92%	271B
AMGEN INC.	29.23x	7.45x	13.34x	2.19%	249B
GILEAD SCIENCES, INC.	-47.64x	7.37x	28.55x	1.99%	205B
Average	32.60x	7.60x	20.93x	1.86%	417.94B
Weighted average by Cap.	36.67x	8.71x	21.55x	1.73%